Innovator國際已開發動力緩衝主動型ETF-4月 IAPR 深 滬
等待開盤 05-20 09:30:00 美东时间
32.6201
-0.113
-0.35%
華盛通- 最 高32.6691
- 今 開32.59
- 成交量 2803股
- 最 低 32.59
- 昨 收 32.7334
- 總市值 1.99亿
- 52周最高 33.07
- 市盈率 靜 --
- 換手率 0.05%
- 52周最低 28.68
- 委 比 -33.33%
- 總股本 610.00万
- 歷史最高 33.07
- 量 比 0.31
- 振 幅 0.24%
- 歷史最低 21.45
- 每 手 1
- 風險率 1.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Healthcare firm Innoviva posts Q2 net income
Overview Innoviva Q2 royalty revenue at $67.3 mln, strong GSK portfolio performance Net product sales rise 54% yr/yr to $35.5 mln, driven by U.S. sales Net income at $63.7 mln, up from a $34.7 mln los...
2025-08-07 04:29
Innoviva Inc. Reports Q2 2025 Results: Net Income Surges to $63.7M, EPS at $1.01, U.S. Net Product Sales Up 54%
Innoviva Inc. (NASDAQ: INVA), a diversified holding company, reported its financial results for the second quarter of 2025, highlighting significant developments and achievements. The company recorded...
2025-08-07 04:05
BRIEF-Briacell Therapeutics’ Subsidiary, BriaPro, Files Patent Application For Immuno-Oncology Platform With Novel Multitargeting Agents
July 29 (Reuters) - Briacell Therapeutics Corp BCT.TO: BRIACELL’S SUBSIDIARY, BRIAPRO, FILES PATENT APPLICATION FOR IMMUNO-ONCOLOGY PLATFORM WITH NOVEL MULTITARGETING AGENTS Source text: ID:nGNXbdCRFY...
2025-07-29 19:41
Innoviva Inc. Reports Q1 2025 Results: Revenue Hits $91.6M, Net Loss of $46.6M, EPS Decline to ($0.74)
Innoviva, Inc. (NASDAQ: INVA) reported its financial results for the first quarter ending March 31, 2025. The company recorded gross royalty revenue of $61.3 million from Glaxo Group Limited, slightly...
2025-05-08 04:09
Gain Therapeutics Inc. to Present at IAPRD World Congress on Parkinson's Disease and Related Disorders
Gain Therapeutics, Inc., a clinical-stage biotechnology company, will present at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease ...
2025-04-30 19:45
